Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
Status:
Completed
Trial end date:
2021-05-03
Target enrollment:
Participant gender:
Summary
This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and
vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic
dermatitis.